PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.
Acute Myelogenous Leukemia|B-cell Acute Lymphoblastic Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm|Chronic Myeloid Leukemia, Blast Crisis
BIOLOGICAL: XmAb14045
Safety as determined by the number of participants with treatment-related adverse events, Treatment-related adverse events as assessed by CTCAE v4.03, Baseline Day 1 through Day 56|Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb14045 dosing, Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb14045 dosing, Baseline Day 1 through Day 56
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.